Glaucoma Clinical Trial
Official title:
Feasibility Study and Preliminary Application Study on Noninvasive Iris Optical Coherence Tomography Angiography (OCTA)
All participants will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens. The main outcomes are iris blood flow density and vascular density.
1. Feasibility study of iris OCTA technology
2. Establishment of iris OCTA database in normal population and analysis of related
factors: (1) different sex; (2) different age; (3) different myopic diopter; (4) 24-hour
diurnal changes from morning to night; (5) before and after mydriasis; (6) different
blood pressure; (7) different intraocular pressure; (8) different blood glucose; (9)
before and after exercise. (10) drinking water, tea, coffee and red wine.
3. Analysis of iris OCTA data related to eye diseases:(1) conjunctivitis; (2) glaucoma; (3)
childhood myopia; (4) uveitis; (5) diabetic retinopathy; (6) retinal detachment; (7)
fundus neovascularization.
4. Influence of commonly used ophthalmic drops on iris OCTA data. Observe the difference of
iris OCTA test data before and after treatment: (1) conjunctivitis treated with
levofloxacin antibiotics; (2) glaucoma treated with prostaglandins, adrenalines and
receptor blockers; (3) childhood myopia treated with atropine drugs (4) uveitis treated
with hormonal drugs. (5) diabetic retinopathy treated with vasodilator.
5. Effect on iris OCTA data before and after ophthalmic surgery. (1) cataract,
phacoemulsification + intraocular lens implantation; (2) glaucoma, iridectomy; (3)
fundus neovascularization, intraocular injection of anti-VEGF; (4) diabetic retinopathy,
vitreous surgery.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06000865 -
Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE
|
N/A | |
| Recruiting |
NCT06278597 -
Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device
|
N/A | |
| Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
| Recruiting |
NCT03274024 -
The Asia Primary Tube Versus Trab (TVT) Study
|
N/A | |
| Completed |
NCT04552964 -
Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma
|
N/A | |
| Recruiting |
NCT01957267 -
Functional and Structural Imaging for Glaucoma
|
||
| Active, not recruiting |
NCT04624698 -
iStent Inject New Enrollment Post-Approval Study
|
N/A | |
| Completed |
NCT04020705 -
The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma
|
N/A | |
| Completed |
NCT03150160 -
Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma
|
Phase 4 | |
| Not yet recruiting |
NCT05581498 -
Glaucoma Exercise as Medicine Study (GEMS).
|
N/A | |
| Recruiting |
NCT02921568 -
Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes
|
N/A | |
| Active, not recruiting |
NCT02901730 -
Clinical Study of LPI With Different Laser Wavelengths
|
N/A | |
| Completed |
NCT02955849 -
A Trial of China Laser and Surgery Study Glaucoma in Rural China
|
Early Phase 1 | |
| Recruiting |
NCT02554214 -
Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device
|
N/A | |
| Recruiting |
NCT02471105 -
Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml
|
Phase 4 | |
| Active, not recruiting |
NCT02390284 -
Stop Retinal Ganglion Cell Dysfunction Study
|
Phase 3 | |
| Completed |
NCT02246764 -
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
|
Phase 3 | |
| Completed |
NCT02653963 -
Triamcinolone for Ahmed Glaucoma Valve
|
N/A | |
| Completed |
NCT02520674 -
Glaucoma Screening With Smartphone Ophthalmology
|
N/A | |
| Completed |
NCT02628223 -
180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma
|
N/A |